Researchers have spent 20 years trying to develop enzyme drugs for celiac disease. A new review reveals exactly what's gone wrong — and maps a path forward.
Takeda has cut a second phase 2 celiac therapy from its pipeline, leaving just one program. What the setback means for patients waiting on alternatives to the gluten-free diet.
Researchers confirm a humanized celiac mouse model accurately mirrors human responses to TG2 inhibition, a key step toward faster drug development.
Three new studies show how patient voices and real-world data are helping drug companies design better celiac disease trials and bring treatments closer to reality.
An experimental drug shows promise for treating celiac disease beyond the gluten-free diet. What celiac families should know about this development.